Applications of iTRAQ-Based Peptidomics in Inflammation Research
- High-Throughput Comparative Capacity: Multiple samples can be analyzed simultaneously in a single LC-MS/MS run, thereby reducing experimental variation.
- High Sensitivity and Quantitative Reproducibility: Compared with label-free methods, iTRAQ provides both peptide identification and relative quantitative analysis with improved multiplexing capability.
- Efficient Detection of Inflammation-Associated Molecular Changes: During inflammatory responses, cytokines, complement components, inflammation-related enzymes, receptors, and other mediators undergo marked dynamic changes. iTRAQ-based analysis can capture abundance changes in these low-abundance or dynamically regulated molecules.
- Sample Processing: Serum, tissue, or cell lysate samples are extracted.
- Protease Digestion: Trypsin digestion is performed to generate peptides suitable for iTRAQ labeling.
- iTRAQ Labeling: Peptides from different treatment groups are labeled separately with different iTRAQ channels, such as 113-118.
- Sample Mixing and Prefractionation: After labeling and mixing, samples are fractionated by HILIC or SCX to reduce sample complexity.
- LC-MS/MS Detection: High-resolution Orbitrap mass spectrometry is used for multiple rounds of data acquisition.
- Data Analysis: Platforms such as Mascot and MaxQuant are used for peptide identification and reporter ion-based quantification.
- Differential Abundance Screening: Candidate differentially abundant peptides or proteins are selected based on thresholds such as fold change ≥1.2 or ≤0.83, together with P values and FDR correction.
- Pathway Enrichment Analysis: GO and KEGG annotation are applied to interpret inflammation-related pathways.
- Targeted Validation: PRM or ELISA is used to validate key inflammatory proteins and provide confirmatory evidence.
iTRAQ is an isobaric isotope-labeling strategy that covalently labels peptide N-termini and lysine side chains. Through 4-plex or 8-plex multiplex labeling, iTRAQ enables simultaneous relative quantification of multiple samples. In tandem mass spectrometry (MS/MS), these isobaric tags fragment to generate characteristic reporter ions, allowing accurate comparison of peptide abundance across different treatment groups. iTRAQ-based peptidomics has been widely applied in inflammation research, including mechanistic investigation, drug response monitoring, and biomarker discovery. When integrated with PRM or ELISA, this approach can help bridge basic research findings with clinical translation.
Why Is iTRAQ-Based Peptidomics Suitable for Inflammation Research?
Applications of iTRAQ-Based Peptidomics in Inflammation Research
Inflammation is a highly complex biological response to infection, tissue injury, or immune stimulation. It involves dynamic regulation of numerous soluble factors, including cytokines, chemokines, and complement proteins, as well as receptors and signal transduction pathways. Conventional methods often fail to comprehensively capture these multidimensional dynamic changes. In contrast, iTRAQ combined with high-resolution mass spectrometry provides a powerful technical platform for systematic investigation of inflammatory processes.
1. Revealing Expression Changes in Inflammatory Mediators
iTRAQ-based peptidomics enables parallel quantification of multiple samples in a single LC-MS/MS analysis by labeling equal amounts of peptides from different treatment groups. This approach markedly improves throughput and comparative efficiency. In inflammation research, it can be used to analyze a broad range of inflammation-associated factors, including:
(1) Acute-Phase Proteins, Such as C-Reactive Protein and Serum Amyloid Proteins: Their dynamic expression changes can be accurately quantified to support assessment of inflammatory severity.
(2) Cytokine Regulatory Proteins: Proteins involved in IL-1/IL-6 regulation, NF-κB signaling regulation, STAT-related pathways, and other immune signaling processes can be analyzed to reveal abnormal mechanisms of immune signal transduction.
(3) Apoptosis- and Autophagy-Related Factors: Important regulators of cell fate under inflammatory conditions, such as caspases and Beclin-1, can also be quantified by iTRAQ-based analysis to determine changes in protein abundance.
2. Inflammatory Pathway Enrichment and Network Modeling
By integrating iTRAQ data with bioinformatics analysis, peptides or proteins that are significantly upregulated or downregulated under inflammatory conditions can be identified and further subjected to functional annotation and pathway enrichment analysis, such as KEGG and GO analysis.
(1) Identification of Activated Pathways: Key inflammatory response pathways, including TNF-α/NF-κB, JAK/STAT, MAPK, and NLRP3 inflammasome pathways, can be identified.
(2) Reconstruction of Regulatory Modules: Protein-protein interaction (PPI) analysis can be used to construct inflammatory regulatory networks and identify key hub proteins.
(3) Preliminary Target Prioritization: Potential therapeutic intervention targets can be prioritized based on expression trends and network centrality.
3. Disease State Classification and Staging
iTRAQ-based peptidomics can also be used for subtype classification and staging studies in inflammatory diseases. Examples include:
(1) Comparison Between Mild and Severe Inflammation: Quantitative differential analysis can identify key molecules that change during early disease stages and progressive inflammatory states.
(2) Prediction of Treatment Response: Biomarker panels constructed from iTRAQ data can be used to predict individual responses to anti-inflammatory drugs, immunosuppressants, and related therapeutic interventions.
(3) Differentiation Between Chronic and Acute Inflammation: Specific molecular signatures can be identified to support disease classification or staging.
4. Revealing Inflammatory Networks Through Integrated Multi-Omics Analysis
In the current era of precision medicine, iTRAQ-based peptidomics is frequently integrated with other omics datasets, including transcriptomics, metabolomics, and phosphoproteomics.
(1) Protein-mRNA Co-Expression Analysis: This analysis helps determine whether changes in protein abundance are driven by transcriptional regulation and supports screening of post-transcriptionally regulated targets.
(2) Integration of Protein Abundance With Metabolic Pathways: This strategy can reveal metabolic reprogramming under inflammatory conditions, such as alterations in lactate metabolism and fatty acid oxidation.
(3) Integration With Post-Translational Modification Omics: Combined analysis with acetylomics or phosphoproteomics can clarify modification-mediated regulatory networks involving inflammatory signaling proteins.
5. Inflammatory Biomarker Discovery and Translational Application
Differentially expressed peptides identified through iTRAQ screening can be further validated using targeted mass spectrometry, such as PRM/MRM, or immunological methods, such as ELISA. These validation strategies support the following translational applications:
(1) Development of Diagnostic Biomarkers for Inflammation: Noninvasive inflammatory biomarkers detectable in blood, urine, and other sample types can be identified.
(2) Discovery of Personalized Therapeutic Targets: Disease subgroup-specific regulatory factors can be identified to guide targeted therapeutic strategies.
(3) Establishment of Pharmacodynamic Evaluation Indicators: Candidate markers can serve as reliable quantitative indicators for confirming drug mechanisms of action and monitoring therapeutic efficacy.
Detailed Experimental Workflow of iTRAQ-Based Peptidomics
MtoZ Biolabs Supports Inflammation Research
MtoZ Biolabs has established comprehensive capabilities in iTRAQ labeling and LC-MS/MS analysis. The platform supports high-throughput workflows suitable for multi-sample comparisons, provides extensive experience in data processing and bioinformatics analysis, and delivers pathway enrichment and target discovery reports. MtoZ Biolabs also offers validation services based on PRM and ELISA to support translational research. A complete QC workflow aligned with GLP/GCLP standards helps ensure data quality suitable for translational and clinical-oriented studies.
iTRAQ-based peptidomics has broad applications in inflammation research, including mechanistic investigation, drug response monitoring, and biomarker discovery. When integrated with PRM or ELISA, it can facilitate effective connection between basic research and clinical translation. With a mature analytical platform and an experienced technical team, MtoZ Biolabs provides full-process iTRAQ solutions to support precision inflammation analysis, biomarker development, and diagnostic translation. Researchers with inflammation-related study needs are welcome to contact us to advance innovation in inflammation research and clinical application.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
